Central illustration.

Interactions between anticoagulants, antiplatelets, fibrinolytics and drugs used to treat coronavirus disease 2019 (COVID-19) patients. Notably, the overall quality of this evidence is very low. This table is based on the COVID-19 Drug Interaction website of the University of Liverpool (www.covid19-druginteractions.org). Gray color: No information found on the website, but interaction seems unlikely according to the summary of product characteristics. Green color: no clinically significant interaction is expected, or potential interaction is likely to be of weak intensity, not requiring additional action/monitoring or dose adjustment. Yellow color: Potential weak interaction which may require additional monitoring (e.g., more frequent international normalized ratio monitoring if on vitamin K antagonist). Orange color: Potential interaction which may require dose adjustment. Red color: The drugs should not be co-administered. ↑ Potential increased exposure to the anticoagulant, antiplatelet, or fibrinolytic drugs. ↓ Potential decreased exposure to the anticoagulant, antiplatelet, or fibrinolytic drugs. *Antibiotics are only indicated in COVID-19 patients if bacterial co-infection is present.